Archives
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Annexin V-FITC/PI Apoptosis Assay Kit: Advanced Apoptosis...
2025-10-19
The Annexin V-FITC/PI Apoptosis Assay Kit empowers researchers to unravel cell death dynamics with precision, distinguishing early and late apoptosis in complex models. Its rapid, one-step workflow accelerates experimental timelines while delivering reliable, high-content data for cancer and drug resistance studies.
-
Phenacetin as a Benchmark in Pharmacokinetic Research
2025-10-18
Harness the unique properties of Phenacetin as a model non-opioid analgesic for advanced pharmacokinetic studies using human stem cell-derived intestinal organoids. This guide breaks down experimental workflows, solubility solutions, and troubleshooting strategies to empower translational drug absorption research.
-
Cyclopamine: Precision Hedgehog Signaling Inhibition in C...
2025-10-17
Cyclopamine is not just another Hedgehog signaling inhibitor—it is a precision tool for dissecting the Smoothened receptor’s role in cancer and developmental models. This guide delivers actionable workflows, comparative advantages, and troubleshooting strategies, empowering researchers to maximize the utility of Cyclopamine in advanced oncological and teratogenic studies.
-
Cyclopamine: Hedgehog Signaling Inhibitor for Advanced Ca...
2025-10-16
Cyclopamine stands at the forefront of cancer and developmental biology research as a precise Hedgehog pathway inhibitor, uniquely enabling the dissection of Smoothened receptor-driven events. Its robust anti-proliferative and pro-apoptotic actions, combined with specialized workflow insights, make it indispensable for researchers targeting tumorigenesis and teratogenicity.
-
Cyclopamine in Translational Research: Precision Hedgehog...
2025-10-15
Explore the strategic integration of Cyclopamine, a potent Hedgehog signaling inhibitor, in translational research. This thought-leadership article unpacks mechanistic insights into Smoothened receptor antagonism, evidentiary advances in developmental and cancer models, and forward-looking guidance for researchers seeking to leverage Cyclopamine’s unique properties for impactful discovery.
-
br Materials and Methods br Results
2025-03-03
Materials and Methods Results A total of 28 NSCLC tumor samples from 26 patients (2 patients with paired tumor samples) were included. According to the initial FISH (Abbott Molecular probes) and IHC results, 13 samples were ALK IHC+FISH+, 5 samples were ALK IHC+FISH−, 2 samples (from the same
-
In the search for more specific inhibitors of uptake Iversen
2025-03-03
In the search for more specific inhibitors of uptake2, Iversen and Salt (1970) speculated that steroids may potentiate the actions of catecholamines on vascular smooth muscle by inhibiting uptake2-mediated catecholamine clearance of the transmitters. They went on to demonstrate that a variety of ste
-
Young et al described the role
2025-03-03
Young et al. [40] described the role of adenine monophosphate-activated protein kinase (AMPK) in the translocation of GLUT4 in the heart. The AMPK is activated during muscle contraction [74] by converting AMP to ATP. The adenosine analog, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), is a c
-
br Conclusions br Funding br Acknowledgements and Disclosure
2025-03-03
Conclusions Funding Acknowledgements and Disclosures We would like to thank veterinarian Angelina Williams and assistants Justin Courson, Ashutosh Jnawali, Mythri Puella, Santoshi Ramachandran, and Zhihui She for support during dissections. We also thank Drs. Vallabh Das, Deborah Otteson an
-
Silk which is a mixture of mainly
2025-03-03
Silk, which is a mixture of mainly SF and sericin, has an extensive history in clinical application as a suture material. Unwanted immune reactions to silk sutures observed early on in their application were assigned to the presence of sericin. However, in vitro and in vivo evaluations of pure SF fi
-
where is the breaking force In the following the
2025-03-03
where is the breaking force. In the following, the details of the simulation are presented and subsequently, the results are discussed. The initial atomic structure is extracted from the crystal structure of single AF (PDB identification 3G37) which consist 12 monomers. As aforementioned 4 monomer
-
Specifically equity injections in a multinational affiliate
2025-03-03
Specifically, equity injections in a multinational affiliate X located in an ACE country can be passed on as lending to another group member Y located in a different country with a high corporate income tax rate. For the group member Y, the interest on the loans is tax deductible, and at the same ti
-
NSC59984 br Materials and methods br
2025-03-03
Materials and methods Results Discussion The brain is endowed with the 5-LOX enzymatic system (Lammers et al., 1996, Lindgren et al., 1984), but its physiological and pathological roles are still not clear. Inflammation is a characteristic of many neurodegenerative diseases such as Alzheime
-
Although experiments on animals and cells indicate
2025-03-03
Although experiments on animals and cells indicate that antioxidant and free radical scavenging agents have protective effects against brain damage, the results of preclinical trials are not as encouraging. Edaravone is a type of free radical scavenging drug that was first used as a neuroprotective
-
MLN another selective Aurora A inhibitor is
2025-03-03
MLN8237, another selective Aurora-A inhibitor is said to be more potent than MLN8054 and to cause less benzodiazepine-like side effects based on structure modulation by the addition of a methoxy group to either end of the MLN8054 molecule. It was studied [62] in a once daily (QD) schedule for 7 days